Author

J.H. Cho

Institution: Samsung Medical Center

Observed institutions: Yonsei University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Samsung Medical Center, Yonsei University Health System, Yonsei Cancer Hospital, The Ohio State University

OpenAlex ID: A5061908681

OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3

2019 · F. Oezkan, K. He, et al. · Journal of Thoracic Oncology · 10

OA 18.02 The Landscape of Alteration of DNA Integrity-Related Genes and Their Association with Tumor Mutation Burden in Non-Small Cell Lung Cancer

2017 · M. Sharpnack, J.H. Cho, et al. · Journal of Thoracic Oncology · 3

P2.08.31 Clinical and Imaging Characteristics Associated With Pathologic Response After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC

2025 · D.Y. Jeong, J. Lee, et al. · Journal of Thoracic Oncology

The Role of Local Prostate and Metastasis-Directed Radiotherapy in the Treatment of Oligometastatic Prostate Cancer

2023 · S.H. Choi, J.G. Lee, et al. · International Journal of Radiation Oncology*Biology*Physics

P1.04-15 Smoking Status Is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer

2019 · M. Sharpnack, J.H. Cho, et al. · Journal of Thoracic Oncology

Works count: 5

Citation count: 13

H-index: 2

I10-index: 1